ANI PHARMACEUTICALS INC
Company Stats
- Market Cap
- $1.7B
- as of Sep 30, 2026
- Shares Outstanding
- 23.0M
- Free Float
- 63.7%
Income Statement
- Revenue
- $883.4M
- Operating Income
- $111.1M
- Net Income
- $78.3M
- EBITDA
- $120.0M
- Non-cash Impairment
- $767,000
- Revenue Growth, 3Y
- 40.8%
- FCF Margin, 3Y Avg
- 16.6%
- FCF Margin, Worst Year
- 7.8%
Cash Flow
- Free Cash Flow
- $171.4M
- FCF Yield
- 10.3%
- Owner FCF Yield
- 8.0%
Balance Sheet
- Cash & Equivalents
- $285.6M
Returns & Capital
- Dividends Paid
- $1.2M
- Dividend Yield
- 0.1%
- Share Repurchases
- $12.2M
- Buyback Yield, 3Y Avg
- 0.6%
- SBC, 3Y Avg
- $29.3M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $883.4M | $171.4M | 19.4% |
| FY2024 | $614.4M | $47.8M | 7.8% |
| FY2023 | $486.8M | $110.1M | 22.6% |
| FY2022 | $316.4M | -$40.1M | -12.7% |
| FY2021 | $216.1M | $765,000 | 0.4% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 9, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
ANI Pharmaceuticals to Offer $560 Million for Egetis
Stronger demand supports expansion as pricing diverges